Literature DB >> 8353034

Surrogate endpoints.

S S Ellenberg.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8353034      PMCID： PMC1968384          DOI： 10.1038/bjc.1993.369

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  22 in total

1.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

2.  Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate.

Authors:  D P Byar
Journal:  Cancer       Date:  1973-11       Impact factor: 6.860

3.  Preliminary analysis of the Concorde trial. Concorde Coordinating Committee.

Authors:  J P Aboulker; A M Swart
Journal:  Lancet       Date:  1993-04-03       Impact factor: 79.321

4.  Acute leukemia after alkylating-agent therapy of ovarian cancer.

Authors:  R R Reimer; R Hoover; J F Fraumeni; R C Young
Journal:  N Engl J Med       Date:  1977-07-28       Impact factor: 91.245

5.  The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia.

Authors:  D E Bergsagel; A J Bailey; G R Langley; R N MacDonald; D F White; A B Miller
Journal:  N Engl J Med       Date:  1979-10-04       Impact factor: 91.245

6.  CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use.

Authors:  J M Taylor; J L Fahey; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

7.  Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup.

Authors:  C A Coltman; D O Dixon
Journal:  Cancer Treat Rep       Date:  1982-04

8.  Studies in variation associated with the measurement of solid tumors.

Authors:  P T Lavin; G Flowerdew
Journal:  Cancer       Date:  1980-09-01       Impact factor: 6.860

9.  Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU).

Authors:  J D Boice; M H Greene; J Y Killen; S S Ellenberg; R J Keehn; E McFadden; T T Chen; J F Fraumeni
Journal:  N Engl J Med       Date:  1983-11-03       Impact factor: 91.245

10.  Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.

Authors:  D Warr; S McKinney; I Tannock
Journal:  J Clin Oncol       Date:  1984-09       Impact factor: 44.544
View more
  10 in total

1.  Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time.

Authors:  Stuart G Baker; Daniel J Sargent; Marc Buyse; Tomasz Burzykowski
Journal:  Biometrics       Date:  2011-08-13       Impact factor: 2.571

Review 2.  An investigator's introduction to statistical considerations in clinical trials.

Authors:  Kathryn Winter; Stephanie L Pugh
Journal:  Urol Oncol       Date:  2019-03-26       Impact factor: 3.498

3.  Surrogate endpoint analysis: an exercise in extrapolation.

Authors:  Stuart G Baker; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2012-12-21       Impact factor: 13.506

Review 4.  Surrogate endpoints in liver surgery related trials: a systematic review of the literature.

Authors:  Liliane Mpabanzi; Kim M C van Mierlo; Massimo Malagó; Cornelis H C Dejong; Dimitrios Lytras; Steven W M Olde Damink
Journal:  HPB (Oxford)       Date:  2012-10-22       Impact factor: 3.647

5.  Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen.

Authors:  B Kristensen; B Ejlertsen; H T Mouridsen; K W Andersen; J B Lauritzen
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials.

Authors:  Stuart G Baker
Journal:  Stat Med       Date:  2017-11-21       Impact factor: 2.373

7.  Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes.

Authors:  Stuart G Baker; Barnett S Kramer
Journal:  Clin Trials       Date:  2014-11-10       Impact factor: 2.486

8.  University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (morning panel discussion).

Authors:  Michael Daniels; Constantine Frangakis; Vivek Charu; Debashis Ghosh
Journal:  Clin Trials       Date:  2015-06-10       Impact factor: 2.486

9.  Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD.

Authors:  Jeffrey K Luttrull; Stephen H Sinclair; Solly Elmann; Bert M Glaser
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

10.  Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action.

Authors:  Nicole A Tillie; Jayson L Parker; Jordan J Feld
Journal:  Can J Gastroenterol Hepatol       Date:  2016-03-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.